Liver Disease
From the Journals
Hepatitis Outlook: November 2016
Baseline hepatitis B core antibody predicts treatment response in chronic HBV patients receiving long-term entecavir, according to a recent study...
Video
VIDEO: Angiogenesis has a role to play in NASH and NAFLD
BOSTON
Conference Coverage
Nonalcoholic fatty liver disease accelerates brain aging
TORONTO – NAFLD seems to accelerate physical brain aging by up to 7 years, according to a new subanalysis of the ongoing Framingham Heart Study....
Conference Coverage
The Liver Meeting 2016 debrief – key abstracts
BOSTON - Amid a plethora of quality research, several abstracts stood out at the annual meeting of the American Association for the Study of Liver...
Conference Coverage
VIDEO: Hepato-adrenal syndrome is an under-recognized source of ICU morbidity
BOSTON – Patients with serious liver disease who also had hepato-adrenal syndrome had significantly longer hospital stays; these patients had...
Conference Coverage
HCV patients with early-stage hepatocellular carcinoma can achieve SVR
Among patients with hepatocellular carcinoma, rates of sustained viral response to direct-acting regimens for hepatitis C virus were 79% for...
Conference Coverage
Early TIPS effective in high-risk cirrhosis patients, but still underutilized
BOSTON – A new study confirms that high-risk cirrhosis patients treated early with a transjugular intrahepatic portosystemic shunt have increased...
Conference Coverage
Metabolomics of liquid biopsies offer a comprehensive look at NAFLD
BOSTON - Metabolomics of liquid biopsies noninvasively identified nonalcoholic fatty liver disease with and without steatosis, and assessed the...
Conference Coverage
Time to consider cirrhosis medical homes
Currently, there are no value-based models for hepatology in the United States. Cirrhosis medical homes could be one way to cut costs and improve...
Conference Coverage
Sofosbuvir/velpatasvir improved patient-reported outcomes, knocked out HCV genotypes 1-6
BOSTON – When given with ribavirin, a fixed-dose combination of sofosbuvir/velpatasvir (Epclusa) achieved a sustained viral response at 12 weeks (...